Cholesterol and APOE genotype interact to influence Alzheimer disease progression

被引:98
作者
Evans, RM
Hui, S
Perkins, A
Lahiri, DK
Poirier, J
Farlow, MR
机构
[1] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA
[3] Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA
[4] Indiana Univ, Sch Med, Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA
[5] McGill Ctr Studies Aging, Montreal, PQ, Canada
关键词
D O I
10.1212/01.WNL.0000125323.15458.3F
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In this retrospective analysis of 443 Alzheimer disease ( AD) patients from a 30-week tacrine trial, change in Alzheimer's Disease Assessment Scale score from baseline to final value was significantly associated with a total serum cholesterol/ APOE genotype interaction. Disease progression in the no-APOE epsilon4 allele/high-cholesterol subgroup was greater than in the normal-cholesterol subgroups with or without epsilon4. Cholesterol levels and APOE genotype may interact to affect AD progression. The results are consistent with preclinical data on cholesterol's effects in AD.
引用
收藏
页码:1869 / 1871
页数:3
相关论文
共 10 条
[1]
ApoE associated with lipid has a reduced capacity to inhibit β-amyloid fibril formation [J].
Beffert, U ;
Poirier, J .
NEUROREPORT, 1998, 9 (14) :3321-3323
[2]
Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease:: A population-based study of African Americans [J].
Evans, RM ;
Emsley, CL ;
Gao, S ;
Sahota, A ;
Hall, KS ;
Farlow, MR ;
Hendrie, H .
NEUROLOGY, 2000, 54 (01) :240-242
[3]
Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease [J].
Farlow, MR ;
Lahiri, DK ;
Poirier, J ;
Davignon, J ;
Schneider, L ;
Hui, SL .
NEUROLOGY, 1998, 50 (03) :669-677
[4]
A 30-WEEK RANDOMIZED CONTROLLED TRIAL OF HIGH-DOSE TACRINE IN PATIENTS WITH ALZHEIMERS-DISEASE [J].
KNAPP, MJ ;
KNOPMAN, DS ;
SOLOMON, PR ;
PENDLEBURY, WW ;
DAVIS, CS ;
GRACON, SI ;
APTER, JT ;
LAZARUS, CN ;
BAKER, KE ;
BARNETT, M ;
BAUMEL, B ;
EISNER, LS ;
CASTELLS, B ;
BOLOURI, R ;
BENNETT, D ;
FORCHETTI, C ;
LEVIN, A ;
BLASS, JP ;
NOLAN, KA ;
GAINES, ER ;
RELKIN, N ;
BORISON, RL ;
DIAMOND, B ;
CELESIA, GG ;
ROSS, AP ;
DEXTER, J ;
DOODY, R ;
LIPSCOMB, L ;
KREITER, K ;
DUBOFF, EA ;
BLOCK, P ;
MARSHALL, D ;
WESTERGAARD, N ;
EARL, NL ;
WYNE, SV ;
HINMANSMITH, E ;
FARLOW, M ;
HENDRIE, HC ;
CARESS, JA ;
FARMER, M ;
HARPER, JE ;
FERGUSON, J ;
FOSTER, NL ;
BARBAS, NR ;
BLUEMLEIN, LA ;
GELB, DJ ;
BERENT, S ;
GIORDANI, B ;
GREENWALD, M ;
BERGMAN, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (13) :985-991
[5]
Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ 1-42 levels [J].
Kuo, YM ;
Emmerling, MR ;
Bisgaier, CL ;
Essenburg, AD ;
Lampert, HC ;
Drumm, D ;
Roher, AE .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 252 (03) :711-715
[6]
Elevated serum total and LDL cholesterol in very old patients with Alzheimer's disease [J].
Lesser, G ;
Kandiah, K ;
Libow, LS ;
Likourezos, A ;
Breuer, B ;
Marin, D ;
Mohs, R ;
Haroutunian, V ;
Neufeld, R .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2001, 12 (02) :138-145
[7]
Alzheimer's disease: the cholesterol connection [J].
Puglielli, L ;
Tanzi, RE ;
Kovacs, DM .
NATURE NEUROSCIENCE, 2003, 6 (04) :345-351
[8]
APOE genotype, plasma lipids lipoproteins, and AD in community elderly [J].
Romas, SN ;
Tang, MX ;
Berglund, L ;
Mayeux, R .
NEUROLOGY, 1999, 53 (03) :517-521
[9]
Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid β peptides [J].
Tokuda, T ;
Calero, M ;
Matsubara, E ;
Vidal, R ;
Kumar, A ;
Permanne, B ;
Zlokovic, B ;
Smith, JD ;
Ladu, MJ ;
Rostagno, A ;
Frangione, B ;
Ghiso, J .
BIOCHEMICAL JOURNAL, 2000, 348 :359-365
[10]
Brain region-dependent increases in β-amyloid and apolipoprotein E levels in hypercholesterolemic rabbits [J].
Wu, CW ;
Liao, PC ;
Lin, C ;
Kuo, CJ ;
Chen, ST ;
Chen, HI ;
Kuo, YM .
JOURNAL OF NEURAL TRANSMISSION, 2003, 110 (06) :641-649